...疫耐受,外源性HSC卵黄囊内移植能更早地与受体HSC竞争,产生更高的嵌合比例;Fan等[7]发现,经门静脉注射(portal vein injection,PV injection)的HSC在7天内迁移至造血、免疫器官,移植后第3天和第7天肝脏、骨髓和胸腺中供体源细胞明显高于尾静脉...
基于12个网页-相关网页
...黄囊内移植能更早地与受体HSC竞争,产生更高的嵌合比例;Fan等[7]发现,经门静脉注射(portal v EIn injection,PV injection)的HSC在7天内迁移至造血、免疫器官,移植后第3天和第7天肝脏、骨髓和胸腺中供体源细胞明显高于尾静脉...
基于2个网页-相关网页
经门静脉注射 portal vein injection ; PV INJECTION
目的利用大鼠异位心脏移植模型,探讨门静脉注射供体脾细胞诱导免疫耐受的机制。
Objective on the rat model of heterotopic heart transplantation, the mechanism of immune tolerance induced by portal venous injection of donor spleen cells was studied.
结论经门静脉注射两种或两种以上供体活细胞可减轻慢性排斥反应,VEGF、ET-1的表达与血管硬化及纤维化程度呈正相关。
Conclusions Injection of two or more kinds of donor live cells may alleviate chronic rejection via decreasing of expressions of VEGF and ET-1 in the grafts.
应用推荐